Answers are grounded in this paper and cite their sources.
Reveals clinical risk combined with genomic scoring guides adjuvant therapy in premenopausal breast cancer, indicating pathways to optimize treatment.
Clinical-risk stratification provided prognostic information that, when added to the 21-gene recurrence score, could be used to identify premenopausal women who could benefit from more effective therapy. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00310180.).
No takes yet. Share an insight, caveat, or question.
Sparano et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: